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The major function of the cardiovascular and ventila-
tory systems is gas transportation between the cells and the
atmosphere. Deficiencies in the function of these systems
are better observed during exercise, because cellular respi-
ration is stimulated and the defects are amplified. Because
each component of the gas transportation system binds the
external medium to internal respiration with a different func-
tion, abnormalities in gas exchanges differ according to the
pathophysiology. Recognizing these differences allows the
examiner to determine which patient’s system is the major
cause of exercise limitations 1.
Nery et al 2 compared the respiratory and cardiovascu-
lar responses to exercise in patients with chronic obstructi-
ve pulmonary disease (COPD), mitral valve disease, and
healthy individuals. Maximal oxygen uptake (VO2max) was
higher in healthy individuals as compared with that in the
patients, and although the latter developed acidosis at the
end of the assessment, that was primarily respiratory in
patients with COPD and totally metabolic in patients with
mitral valve disease. The ratio between pulmonary ventila-
tion and oxygen consumption, the so-called oxygen ventila-
tory equivalent (VEO2), was higher in the 2 groups of patien-
ts as compared with that in the control group, and the venti-
latory reserve was significantly lower in patients with COPD
(13%) as compared with that in mitral patients (49%) and the
control group (44%). These findings indicate that patients
with mitral valve disease have exercise limitations due to the
cardiovascular response of the oxygen transportation sys-
tem, this being the primary factor of their functional limita-
tion; on the other hand, patients with COPD are impaired by
ventilatory limitations.
According to Weber et al 3, the cause of dyspnea, whe-
ther cardiac or ventilatory, may be determined by cardiopul-
monary exercise testing with the following criteria: in
patients with heart disease, maximal oxygen uptake and
Objective – To differentiate the nature of functional
cardiorespiratory limitations during exercise in indivi-
duals with chronic obstructive pulmonary disease (COPD)
or congestive heart failure (CHF) and to determine indica-
tors that may help their classifications.
Methods – The study comprised 40 patients: 23 with
COPD and 17 with CHF. All individuals underwent maxi-
mal cardiopulmonary exercise testing on a treadmill.
Results - The values of peak gas exchange ratio (R
peak), peak carbon dioxide production (VCO2 peak), and
peak oxygen ventilatory equivalent (VEO2 peak) were
higher in the patients with CHF than in those with COPD,
and, therefore, those were the variables that characterized
the differences between the groups. For group classifica-
tion, the differentiating functions with the R peak, VCO2
peak (L/min), and VEO2 peak variables were used as fol-
lows: group COPD: - 44.886 + 78.832 x R peak + 5.442 x
VCO2 peak + 0.336 x VEO2 peak; group CHF: - 69.251 +
89.740 x R peak + 8.461 x VCO2 peak + 0.574 x VEO2 peak.
The differentiating function, whose result is greater, cor-
rectly classifies the patient’s group as 90%.
Conclusion - The R peak, VCO2 peak, and VEO2 peak
values may be used to identify the cause of the functional
cardiorespiratory limitations in patients with COPD and
CHF.
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hypercapnia. The patients were taking b2-agonist, anticholi-
nergic agents, oral or inhalant corticoid, or methylxanthine, or
both, in optimized doses.
Group II comprised 17 individuals with CHF from the
cardiomyopathy outpatient clinic of the discipline of cardio-
logy of the UNIFESP/EPM, candidates for cardiac transplan-
tation. Twelve were males and 5 females, with a mean age of
44.4 years (29 to 67) and a mean ejection fraction of 25.5±
10.2%. They were in NYHA functional class I to IV. In regard
to the cause of the cardiomyopathy, of the 17 patients, 6 were
classified as having ischemic heart disease, 6 as having cha-
gasic heart disease, and 5 as having idiopathic heart disease.
These patients with CHF underwent spirometry to eliminate
ventilatory obstruction according to the requirements of the
cardiac transplantation protocol. Two patients had cardiac
pacemakers. The patients were taking an angiotensin-con-
verting enzyme inhibitor, diuretics, digitalis, beta-blockers,
amiodarone, or nitrate, or both, in optimized doses.
This study was submitted to and approved by the
committee on ethics and research of the Universidade Fe-
deral de São Paulo/Escola Paulista de Medicina – Hospital
São Paulo. The patients were informed about the study,
and, after reading the information letter, they signed a formal
written consent.
The 2 groups underwent maximal cardiopulmonary
exercise testing on a treadmill (Lifestride – mod. 7500). The
patient inhaled environmental air, and the expired air was
analyzed with the Vista Mini CPX metabolic system (Vacu-
med, USA), which performed measurements of air volume,
fractions of oxygen and carbon dioxide, and calculated the
values of oxygen consumption, carbon dioxide production,
and pulmonary ventilation, expressing the results every 30
seconds. All tests were monitored by the computerized
ergometric system ERGO-S (Dixtal, São Paulo, Brazil). The
peripheral saturation of oxygen (SpO2) was determined with
a Dixtal DX 2405 pulse oximeter (São Paulo, Brazil).
The Harbor protocol 1 was used for the patients with
pulmonary disease, with a constant velocity between 1.6
and 4 km/h according to the patient’s functional limitations,
which were determined by previous tests. The protocol
comprised a first stage of 3-minutes duration, with no incli-
ne, followed by stages of 1-minute duration and 1% increa-
ses in incline. The protocol used for the patients with heart
disease was proposed by Weber et al 3 with a load increase
every 2 minutes.
In all tests, the patient’s exhaustion determined the
interruption of the exertion phase.
Peak oxygen consumption was expressed in milliliters
per kilo of weight per minute (mL/kg/min), in liters per mi-
nute (L/min), and as a percentage of maximal oxygen upta-
ke previewed for sex and age. Peak oxygen consumption
was calculated with the equations proposed by Barros
Neto et al 7: VO2max = 52.727 – 0.3956 x age (male sex) and
VO2max = 42.434 – 0.261 x age (female sex). These equa-
tions were developed based on the results of tests perfor-
med in sedentary individuals.
Means and standard deviations of the variables were
anaerobic threshold are reached, but they are below nor-
mal, while in patients with ventilatory limitations, they are
not reached. The maximal ventilation values during exercise
do not exceed 50% of maximal voluntary ventilation in
patients with cardiac limitations and exceed 70% in patients
with ventilatory limitations. Peripheral oxygen saturation
does not drop below 90% in patients with heart disease, and
hypoxemia frequently appears in patients with pulmonary
disease.
Although no consensus about how to quantify the
maximal ventilatory capacity exists, the following indicators
suggest the presence of ventilatory limitations during exer-
cise 4: maximal ventilation during exercise approaches 100%
of maximal voluntary ventilation or maximal sustained ven-
tilation for 4 minutes; determination of the flow-volume loop
during exercise as compared with the flow-volume loop at
rest may indicate a limitation in the expiratory flow; the
absence of an anaerobic threshold during exercise; and limi-
tation in the increase of the oxygen (VEO2) and carbon dio-
xide (VECO2) ventilatory equivalents.
An individual is considered to reach VO2max when,
during maximal exercise, the progressive increase in the
loads does not increase VO2 by more than 150 mL/min, and a
plateau is graphically obtained 5; when this plateau is not
reached, the highest VO2 is called peak oxygen consump-
tion (VO2 peak) 
1.
Although the cardiopulmonary exercise test is funda-
mental to the differential diagnosis of dyspnea, a small
number of studies compares the metabolic and cardiorespi-
ratory responses during exercise in patients with obstructi-
ve pulmonary diseases and congestive heart failure (CHF).
This study aimed at differentiating the nature of functional
limitation at maximal exercise in individuals with chronic
obstructive pulmonary disease from that in individuals with
congestive heart failure and at identifying indicators that
may help in classifying these 2 clinical conditions by using
the results obtained in cardiopulmonary exercise tests.
Methods
This study comprised 40 individuals divided into 2
groups. Group I comprised 23 individuals with COPD from the
pulmonary rehabilitation program of the Center of Rehabi-
litation of UNIFESP/EPM - Lar Escola São Francisco. Of the
23 patients, 18 were males and 5 were females, with a mean age
of 65.5 years (36 to 77). A 36-year-old patient had a1-antitrip-
sin deficiency. On pulmonary function testing after broncho-
dilation, the following mean values were obtained: forced
vital capacity (FVC) of 2.87±0.86 L (84±18.1% of the previe-
wed); forced expiratory volume in 1 second (FEV1) of 1.04±
0.35 L (39.9±10.8% of the previewed theoretical value); and
FEV1/FVC ratio of 37.5±9.2%. Nine patients were classified as
having moderate obstruction, and 14 patients as having
severe obstruction 6. The mean value of the partial pressure
of oxygen (PaO2) in the arterial blood was 68.3±6.7 mm Hg, of
the partial pressure of carbon dioxide (PaCO2) in the arterial
blood was 37.8±4.5 mm Hg, and no patient had hypoxemia or
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determined, and, to test the significance of the difference bet-
ween the means of the 2 groups (individuals with pulmonary
disease and individuals with heart disease) for each variable,
the t test for independent samples with equal variances was
applied. Aiming at establishing a criterion of classification for
patients, a differentiating analysis was performed according
to Fisher’s criterion, and multiple regression was applied to
the ergospirometric variables to identify significant informa-
tion for differentiating between the groups 8.
Results
Body weight, height, and body mass index of the indi-
viduals with pulmonary disease were similar to those of the
individuals with heart disease (tab. I).
Twenty individuals with pulmonary disease had
oxyhemoglobin desaturation values on pulse oximetry
below 90% during exertion (mean SpO2 at rest = 95±1.3%;
and mean SpO2 at peak exertion = 84.7±4.6%); on the other
hand, no patient with heart disease had SpO2 values below
90% on pulse oximetry (mean SpO2 at rest = 97.3±0.6%; and
mean SpO2 at peak exertion = 95.7±1.4%).
The patients with COPD with oxyhemoglobin desatu-
ration below 88% received oxygen supplementation during
recovery. Although many patients had complex cardiac
arrhythmias (mainly those with heart disease), administra-
tion of antiarrhythmic drugs was not required, because all
arrhythmias ceased with exercise interruption.
The greatest oxygen consumption values (VO2 peak)
reached during exercise were 17.5±3.2 mL/kg/min (66.9±
13.3% of that previewed for sex and age) for the patients
with pulmonary disease, and 19.3±3.7 mL/kg/min (57.6±
12.7% of that previewed) for the patients with heart disease;
no significant difference was observed between the groups.
The 2 groups of patients had a VO2 peak value much lower
than that previewed for sex and age, and the peak oxygen
consumption values, expressed in mL/kg/min or L/min, were
similar in the 2 groups (tab. II).
The anaerobic threshold could be determined by
using the ventilatory method only in 6 (26%) of the 23
patients with COPD; it could not be determined in the other
patients, because they had an irregular ventilatory pattern.
In the patients with CHF, the anaerobic threshold could be
determined in all patients (tab. II). No difference was obser-
ved in peak heart rate (HR peak) and in peak oxygen pulse
between the 2 groups (tab. II).
Although the peak pulmonary ventilation, peak cur-
rent volume, and peak respiratory rate values in the patients
with heart disease were higher than those in the patients
with COPD, they were not pertinent for differentiating bet-
ween the groups (tab. II).
The values of peak gas exchanges (R peak), peak
carbon dioxide production (VCO2 peak), and peak oxygen
ventilatory equivalent (VEO2 peak) were greater in patients
with heart failure than in those with obstructive pulmonary
disease, and these were the variables characterizing the
differences between the groups (tab. III). For group classifi-
cation, the differentiating functions with the R peak, VCO2
peak (L/min), and VEO2 peak variables were used as follows:
COPD group: - 44.886 + 78.832 x R peak + 5.442 x VCO2 peak +
0.336 x VEO2 peak; CHF group: - 69.251 + 89.740 x R peak +
8.461 x VCO2 peak + 0.574 x VEO2 peak.
Applying the values of R peak, VCO2 peak, and VEO2
peak to the 2 differentiating functions, the greatest result
correctly classifies (in 90.0% of the cases) the group the
patient belongs to.
The mean peak carbon dioxide ventilatory equivalent
(VECO2 peak) value, although higher in the patients with
CHF than in those with COPD, was not important for diffe-
rentiating between the groups (tab. III).
Discussion
Maximal oxygen uptake is the most important physio-
logical measurement for defining cardiorespiratory functio-
Table I – Weight, height, and body mass index (BMI) in patients with
pulmonary and heart diseases expressed as mean ± standard deviation
Variable  Pulmonary disease  Heart disease  P
Weight (kg)  65.1 ± 13.7 64±15.2 0.81
Height (cm)  162.7 ± 09 163.7±10.9 0.75
BMI (kg/m2)  24.4 ± 04.3 23.7 ± 4.2 0.58
Table II - Mean values and standard deviations of peak oxygen consump-
tion (VO2 peak), anaerobic threshold (AT), peak heart rate (HR peak),
peak oxygen pulse (peak O2 pulse), peak pulmonary ventilation (VE peak),
peak current volume (VC peak), and peak respiratory rate (f peak) of the
23 patients with pulmonary disease and 17 patients with heart disease
Variable Pulmonary disease Heart disease P
VO2 peak (mL/kg/min) 017.5 ±03.2 019.3 ± 03.7 0.10
VO2 peak (L/min) 001.16 ±00.39 001.24 ± 00.4 0.54
AT * (mL/kg/min) 014.6 ±01.7 013.8 ± 03 0.51
HR peak (bpm) 133.2 ±16 137.1 ± 20.8 0.51
Peak O2 pulse (mL/beat) 008.7 ±02.8 009.1 ± 03 0.64
VE peak (L/min) 037.3 ±12.3 058.7 ± 18.4 <0.001
VC peak (L) 001.12 ±00.33 001.57 ± 00.5 0.002
f peak (breathings/min) 034.3 ±06 039.1 ± 06.9 0.02
* 6 patients with pulmonary disease and 17 patients with heart disease
Table III - Descriptive measures of the peak gas exchange ratio (R
peak), peak carbon dioxide production (VCO2 peak), peak oxygen
ventilatory equivalent (VEO2 peak), and peak carbon dioxide
ventilatory equivalent (VECO2 peak) of the 23 patients with pulmonary
disease and 17 patients with heart disease
Variable Pulmonary disease Heart disease P
R peak * 00.91± 0.09 01.08 ± 00.11 <0.001
VCO2 peak * (L/min) 01.05± 0.38 01.31 ± 00.41 0.040
VEO2 peak * 33.2 ± 6.7 50.4 ± 11.4 <0.001
VECO2 peak 37.2 ± 7.6 46.2 ± 09.9 0.002
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nal capacity. The direct collection of the expired gases du-
ring exercise is necessary for clinical or investigative situa-
tions, such as congestive heart failure and sports training,
for the direct determination of VO2max and anaerobic thre-
shold 9. In patients with COPD, the variables obtained on
cardiopulmonary tests are also the best indicators of aerobic
potency 6, and, as already indicated, those tests are funda-
mental for the differential diagnosis of the cause of dyspnea.
All tests performed in this study were maximal, becau-
se the tests interrupted due to clinical criteria before the
patient reached exhaustion were excluded from the sample.
However, we preferred to adopt the nomenclature of peak
oxygen consumption instead of maximal oxygen uptake,
because the VO2 plateau was not always reached.
The group of patients with obstructive pulmonary
disease had a mean age greater than that of patients with
heart disease. This occurred because the incidence of chro-
nic obstructive pulmonary disease markedly increases with
age 6; on the other hand, the patients with heart disease were
younger, because the younger were given priority for car-
diac transplantation. Maximal oxygen uptake decreases as
age increases after 25 years of age 10. However, VO2 peak
measured was much lower that that previewed for sex and
age in the 2 groups, and the values of VO2 peak measured
were very similar in the 2 groups. We believe that, despite
the age difference between the groups, the cardiorespirato-
ry limitation to exercise was caused by the disease in both
groups.
The cause of cardiomyopathy in the patients with
CHF varied. However, Yazbek Jr et al 11 compared the modifi-
cations in the variables obtained with the cardiopulmonary
exercise test in groups of patients with ischemic cardio-
myopathy, idiopathic cardiomyopathy, or cardiomyopathy
due to Chagas’ disease. Those authors found no signi-
ficant difference in the 3 groups. Therefore, the fact that we
studied patients with cardiomyopathies of different causes
may not have influenced our results.
We recognize that the lack of a healthy control group,
the reduced number of patients studied in both groups, and
the use of a different protocol for each group are limitations
of this study that may have influenced the results.
However, the results of VO2 peak obtained in this stu-
dy are similar to those reported in the literature both for
patients with pulmonary disease 2,12,13 and patients with
heart disease 14-17.
As expected, most patients with COPD (87%) had oxy-
hemoglobin desaturation below 90% during exercise, which
suggests worsening of gas exchange during maximum
exertion in that group of patients 3. No patient with CHF had
oxyhemoglobin desaturation below 90% during exercise.
The anaerobic threshold was determined by using the
ventilatory method in only 26% of the patients with COPD,
which was expected, because the impossibility of determi-
ning this index is considered one of the criteria of ventila-
tory limitation 3,4. On the other hand, the fact that the venti-
latory anaerobic threshold was determined in all patients
with heart disease was also expected, because that index
was initially described in patients with heart disease 18, and,
like VO2max, was used to classify patients functionally 
3.
The values of peak heart rate and peak oxygen pulse
were similar in both groups; therefore, these variables are
not important for differentiating between patients with
COPD and CHF. Although the mean values of peak ventila-
tion, peak current volume, and peak respiratory rate were
greater in patients with heart disease than in patients with
pulmonary disease, the differences were not important for
classifying the patients into the groups.
The peak values of carbon dioxide production, of gas
exchange ratio, and of oxygen ventilatory equivalent were
greater in patients with heart disease than those in patients
with pulmonary disease, allowing characterization of the
differences between the groups and the use of the differen-
tiating functions to classify the patients in each group. The
peak values of carbon dioxide ventilatory equivalent,
although greater in patients with heart disease as compared
with those in patients with pulmonary disease, were not
important for classifying those patients.
These results seem to agree with those reported in the
literature, because VEO2 usually decreases to its lowest
values in the anaerobic threshold, and then begins to
increase, and VECO2 decreases to its lowest values in the
point of respiratory compensation, which is triggered in
response to metabolic acidosis, and then begins to increase
continuously 1.
Patients with obstructive pulmonary disease usually
have an altered ventilation/perfusion ratio, and, therefore,
their VECO2 is high. However, due to their impaired respira-
tory mechanics, their ventilation is limited and those
patients do not usually hyperventilate in response to meta-
bolic acidosis. That is why, despite metabolic acidosis,
VECO2 does not increase in tests with increasing loads. The
normal response of VEO2 is to increase the load above the
anaerobic threshold, and this increase depends on the
magnitude of lactic acidosis and sensitivity of the chemore-
ceptors to acidosis. VEO2 does not increase above the anae-
robic threshold if the chemoreceptors for detecting the
increase in H+ are not sensitive. Patients with COPD may not
reach their lower VEO2 levels during maximal exercise 
1,
because of the sensitivity of the chemoreceptors.
On the other hand, patients with heart failure have an
exaggerated ventilatory response in regard to energy needs 1.
According to our understanding, the low VCO2 peak
and R peak values may be explained by the same factors
implicit in the explanation of the low VEO2 peak and VECO2
peak values found in the tests of patients with COPD. These
patients do not manage to increase their carbon dioxide
removal because pulmonary ventilation does not effectively
increase, and the gas exchange ratio does not also increase
as expected. It is important to stress that R peak values
lower than 1 indicate that the VECO2 peak value is necessa-
rily greater than VEO2 peak, and that the patient is not elimi-
nating carbon dioxide as expected.
It is worth noting that the R peak value in tests of
patients with COPD and CHF is not valued much by most
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authors. Although this variable is extremely altered with
voluntary respiratory maneuvers, the results of other
studies have also suggested that R peak values are lower in
patients with COPD with a greater obstruction on cardio-
pulmonary exercise testing 19,20. We emphasize that our
sample comprised patients with pulmonary disease with
moderate to severe obstruction on cardiopulmonary exer-
cise testing, ie, patients expected to have lower R values
(and, therefore, lower ventilation) on maximal exercise.
On the other hand, patients with heart disease have no
difficulty in eliminating carbon dioxide, and R peak values
greater than 1 are expected in their tests 21-23.
Because of these considerations, we believe that our
results of R peak and VCO2 peak obtained in patients with
obstructive pulmonary disease and heart failure were as
expected.
The VECO2 peak values were greater in patients with
heart disease as compared with those in patients with pul-
monary disease, but were not important in the classification
of these patients perhaps due to the reduced number of
patients studied and the use of different protocols for each
group of patients.
We also believe that the differentiating functions
should not be randomly used to identify the cause of func-
tional limitations in patients with COPD and CHF, because of
the limitations of this study already cited.
In conclusion, R peak, VCO2 peak, and VEO2 peak va-
lues may be used as auxiliary tools in the differential diagno-
sis of the cause of the cardiorespiratory functional limitations
of patients with COPD and CHF. The numeric results of these
variables, applied to their respective differentiating functions,
may be useful for classifying patients with COPD or CHF.
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